Cellectis SA (CLLS) has released an update.
Cellectis SA’s UCART22, a gene-edited CAR T-cell product candidate, has received Orphan Drug and Rare Pediatric Disease Designations from the FDA for its potential to treat Acute Lymphoblastic Leukemia (ALL), a rapidly progressing and typically fatal disease if untreated. This recognition could accelerate and reduce costs of development and approval, and suggests UCART22 as a promising therapy for ALL patients who have limited treatment options. Encouraging clinical data indicates a high preliminary response rate, with further updates expected by year-end 2024.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
